Expression of total and phospho 4EBP1 in metastatic and non‑metastatic renal cell carcinoma

Naito,Sei; Ichiyanagi,Osamu; Ito,Hiromi; Kabasawa,Takanobu; Kanno,Hidenori; Narisawa,Takafumi; Fukuhara,Hiroki; Yagi,Mayu; Kurota,Yuta; Yamagishi,Atsushi; Sakurai,Toshihiko; Nishida,Hayato; Kawazoe,Hisashi; Yamanobe,Takuya; Kato,Tomoyuki; Makhov,Peter; Kolenko,Vladimir  M.; Yamakawa,Mitsunori; Tsuchiya,Norihiko

doi:10.3892/ol.2019.10033

Expression of total and phospho 4EBP1 in metastatic and non‑metastatic renal cell carcinoma

Authors:
- Sei Naito
- Osamu Ichiyanagi
- Hiromi Ito
- Takanobu Kabasawa
- Hidenori Kanno
- Takafumi Narisawa
- Hiroki Fukuhara
- Mayu Yagi
- Yuta Kurota
- Atsushi Yamagishi
- Toshihiko Sakurai
- Hayato Nishida
- Hisashi Kawazoe
- Takuya Yamanobe
- Tomoyuki Kato
- Peter Makhov
- Vladimir M. Kolenko
- Mitsunori Yamakawa
- Norihiko Tsuchiya
View Affiliations

Affiliations: Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Yamagata 990‑9585, Japan, Department of Pathological diagnostics, Yamagata University Faculty of Medicine, Yamagata, Yamagata 990‑9585, Japan, Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Published online on: February 12, 2019 https://doi.org/10.3892/ol.2019.10033
Pages: 3910-3918
Copyright: © Naito et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eukaryotic translation initiation factor 4E‑binding protein 1 (4EBP1) is phosphorylated and activated by mammalian target of rapamycin complex 1, which serves as a regulator of cell growth, cell survival, metastasis and angiogenesis in many types of cancer. The aim of this study was to evaluate the role of phosphorylated 4EBP1 (p4EBP1) in primary renal cell carcinoma (RCC) as a biomarker in metastatic RCC (mRCC) and non‑mRCC cohorts. Primary tumor tissue from 254 non‑mRCC and 60 mRCC patients were immunohistochemically stained for t4EBP1 and p4EBP1. The disease‑free interval (DFI) categorized by the expressions and clinical parameters were assessed by univariate and multivariate analysis in the non‑mRCC cohort. Then, the cause‑specific survival (CSS) was assessed in the mRCC cohort by the same methods as used in the non‑mRCC cohort. In the non‑mRCC cohort, patients with t4EBP1 expression had no RCC recurrence. Patients with p4EBP1 expression had the shorter DFI in univariate analysis (P=0.037). p4EBP1 and pT1b‑4 expression levels were independent predictors for de novo metastasis. In the mRCC cohort, intermediate/poor MSKCC risk, non‑clear cell RCC, and no p4EBP1 expression were correlated with poor CSS on multivariate analysis. Expression of p4EBP1 could be a predictive biomarker for de novo metastasis in non‑mRCC patient cohort. By contrast, mRCC patients showing no p4EBP1 expression had shorter CSS than patients with p4EBP1 expression.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Moch H, Cubilla AL, Humphrey PA, Reuter VE and Ulbright TM: The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
3	Greef B and Eisen T: Medical treatment of renal cancer: New horizons. Br J Cancer. 115:505–516. 2016. View Article : Google Scholar : PubMed/NCBI
4	Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M, Kuczyk MA, et al: Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol. 69:4–6. 2016. View Article : Google Scholar : PubMed/NCBI
5	Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, et al: Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 45:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
6	Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P and Mole DR: Hypoxia, hypoxia-inducible transcription factors and renal cancer. Eur Urol. 69:646–657. 2016. View Article : Google Scholar : PubMed/NCBI
7	Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918. 2012. View Article : Google Scholar : PubMed/NCBI
8	Bramham CR, Jensen KB and Proud CG: Tuning specific translation in cancer metastasis and synaptic memory: Control at the MNK-eIF4E axis. Trends Biochem Sci. 41:847–858. 2016. View Article : Google Scholar : PubMed/NCBI
9	Guo J, Chakraborty AA, Liu P, Gan W, Zheng X, Inuzuka H, Wang B, Zhang J, Zhang L, Yuan M, et al: pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 353:929–932. 2016. View Article : Google Scholar : PubMed/NCBI
10	Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M and Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 63:917–926. 2003. View Article : Google Scholar : PubMed/NCBI
11	Achermann C, Stenner F and Rothschild SI: Treatment, outcome and prognostic factors in renal cell carcinoma-a single center study (2000–2010). J Cancer. 7:921–927. 2016. View Article : Google Scholar : PubMed/NCBI
12	Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG and Kolenko VM: Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther. 11:1510–1517. 2012. View Article : Google Scholar : PubMed/NCBI
13	Naito S, Makhov P, Astsaturov I, Golovine K, Tulin A, Kutikov A, Uzzo RG and Kolenko VM: LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma. Br J Cancer. 116:1203–1207. 2017. View Article : Google Scholar : PubMed/NCBI
14	Ichiyanagi O, Naito S, Ito H, Kabasawa T, Narisawa T, Kanno H, Kurota Y, Kurokawa M, Fukuhara H, Sakurai T, et al: Levels of 4EBP1/eIF4E activation in renal cell carcinoma could differentially predict its early and late recurrence. Clin Genitourin Cancer. 16:e1029–e1058. 2018. View Article : Google Scholar : PubMed/NCBI
15	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
16	Motzer RJ, Bacik J, Murphy BA, Russo P and Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
17	Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J and Ramón y Cajal S: 4E-binding protein 1: A key molecular ‘funnel factor’ in human cancer with clinical implications. Cancer Res. 67:7551–7555. 2007. View Article : Google Scholar : PubMed/NCBI
18	No JH, Jeon YT, Park IA, Kim YB, Kim JW, Park NH, Kang SB, Han JY, Lim JM and Song YS: Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol. 121:8–12. 2011. View Article : Google Scholar : PubMed/NCBI
19	Coleman LJ, Peter MB, Teall TJ, Brannan RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V, Verghese ET, et al: Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer. 100:1393–1399. 2009. View Article : Google Scholar : PubMed/NCBI
20	Campbell L, Jasani B, Griffiths DF and Gumbleton M: Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. Am J Cancer Res. 5:2838–2848. 2015.PubMed/NCBI
21	Joshi S and Platanias LC: Mnk kinase pathway: Cellular functions and biological outcomes. World J Biol Chem. 5:321–333. 2014. View Article : Google Scholar : PubMed/NCBI
22	Nakai Y, Miyake M, Morizawa Y, Hori S, Tatsumi Y, Anai S, Onishi S, Tanaka N and Fujimoto K: Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. Oncol Rep. 37:227–234. 2017. View Article : Google Scholar : PubMed/NCBI
23	Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, et al: Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int. 114:81–89. 2014. View Article : Google Scholar : PubMed/NCBI
24	Xin H, Zhang C, Herrmann A, Du Y, Figlin R and Yu H: Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI